Melanoma vaccines: mixed past, promising future. - Wikidata - wikimedia - TriplyDB

Melanoma vaccines: mixed past, promising future.

Melanoma vaccines: mixed past, promising future.

http://www.wikidata.org/entity/Q34235476

about

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Advances in immunotherapy for melanoma management.Particulate inorganic adjuvants: recent developments and future outlook.Immuno-oncology combinations: raising the tail of the survival curve.The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.

P2860

Q26796314-3894815E-3568-4802-9C9B-32025B410A63 Q37375978-54A052EB-B12B-4129-B411-CEFE5D6E4064 Q38286377-C069B3B1-1185-4259-ABBD-8A184EDC03C6 Q42421273-B3A0B69D-703E-443C-8A00-376BFFF279E9 Q42427640-3B4F002D-FD37-4FE2-8E99-A3909A2B0265 Q46847441-71447411-5CF8-4F7F-AFA9-2F5374FF9A30 Q48128794-1C58C4F2-25D0-446A-AFD0-16E045322A61 Q52592731-C0EDBFAB-EB38-4E8B-A362-D05E973A4EAC

P2860

Melanoma vaccines: mixed past, promising future.

http://www.wikidata.org/entity/Q34235476

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Melanoma vaccines: mixed past, promising future.

@ast

Melanoma vaccines: mixed past, promising future.

@en

Melanoma vaccines: mixed past, promising future.

@nl

type

label

Melanoma vaccines: mixed past, promising future.

@ast

Melanoma vaccines: mixed past, promising future.

@en

Melanoma vaccines: mixed past, promising future.

@nl

prefLabel

Melanoma vaccines: mixed past, promising future.

@ast

Melanoma vaccines: mixed past, promising future.

@en

Melanoma vaccines: mixed past, promising future.

@nl

P1433

Q34235476-4A55B7A8-9091-439A-B99D-1DBB649952CF

P1476

Q34235476-63AE9DAB-7229-45DE-A4DF-AB1D524288E7

P2093

Q34235476-1D89E042-0703-41AB-94A2-08125E6C9EB6

Q34235476-5EF58593-9709-407D-8E7C-3CD823F6D354

Q34235476-884B76AE-C789-4220-A43C-CD0B1C50F0B8

P2860

Q34235476-00E55B0B-6591-4596-A174-0EB1A686E7B4

Q34235476-044EB97C-0F6B-4597-A215-2E337F7EA1CB

Q34235476-19611CBC-E0F3-427B-BD31-88836A330861

Q34235476-1DF49F0A-FF83-4959-8EF6-3E684FAD5A11

Q34235476-343C07FA-4A9C-42B2-9BDB-9F6D5B878230

Q34235476-37D36CB9-07B3-430A-A6BB-A1FF219B94E9

Q34235476-37FB7CF7-E2CF-4DF0-9665-7E5FB14F3E7F

Q34235476-3ED82383-E03E-46CD-9C6C-0856F7AE0D1F

Q34235476-44954007-B006-4C46-853E-263E4C3CE6D8

Q34235476-44D555BC-1F04-463E-A658-3C5967F9CF06

P304

Q34235476-E86DC70B-A0A0-4B49-8651-FEC3727E7B27

P31

Q34235476-8026A977-C28B-468D-A27E-AEE618C974E9

Q34235476-cd5eb9bd-1292-4e0a-ae45-e36a5d2a0f77

P356

Q34235476-284A2E16-3CB3-4941-85CA-673857C7CF97

P433

Q34235476-A9359317-9F29-437E-A0B3-00AAAE210CDA

P478

Q34235476-3D7DBA5C-0E28-4070-885A-1E3F4BCA90F0

P577

Q34235476-925BC777-8B9B-4FBE-BAD9-2DAD749BC4D1

P698

Q34235476-CD6DD069-0F89-418C-82F8-675D7E409D4D

P932

Q34235476-69141D47-2E10-4F47-B5C6-7C6563894646

P356

J.SUC.2014.07.005

P1433

Surgical Clinics of North America

P1476

Melanoma vaccines: mixed past, promising future.

@en

P2093

Delphine J Lee

http://www.w3.org/2001/XMLSchema#string

Junko Ozao-Choy

http://www.w3.org/2001/XMLSchema#string

Mark B Faries

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Paul Ehrlich's magic bullets

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

P304

1017-30, viii

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SUC.2014.07.005

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25245965

http://www.w3.org/2001/XMLSchema#string

P932

4173123

http://www.w3.org/2001/XMLSchema#string